Investor Presentation First Nine Months of 2023
118
Investor presentation
First nine months of 2023
EMEA at a glance
EMEA
Million
300
Diabetes trend
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
I
19%
I
I
I
200
I
DKK
billion
25%
150
First nine months
MS
of 2023
Sales
(mDKK)
Growth²
Injectable GLP-13
12,683
34%
100%
RybelsusⓇ
3,036
208%
80%
Total GLP-1
15,719
50%
100
GLP-1
I
37.8%¹
Total insulin4
13,775
2%
60%
260
Other Diabetes care5
496
-7%
Insulin
100
195
2.6%1
40%
Diabetes care
29,990
23%
158
50
Obesity care
3,983
61%
20%
OAD
13.2%1
Diabetes & Obesity
0
2021
33,973
26%
0
0%
care
2030
2045
Aug
2018
Aug
2023
Rare disease7
4,188
-18%
Population with diabetes
Diabetes growth rate
Total
38,161
19%
-GLP-1 MS
-Insulin MS
OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021; EMEA: Europe, Middle East and Africa
1 CAGR calculated for 5-year period; Competitor insulin value market shares, as of Aug
2023: Novo Nordisk 48%, Others 52%; Competitor GLP-1 value market shares, as of
Aug 2023: Novo Nordisk 63%, Others 37%. OAD: Oral anti-diabetic; MS: Market share;
Source: IQVIA MAT, Aug 2023 value figures; Market values are based on the list prices
2 At Constant exchange rates; 3 Comprises Victoza®, OzempicⓇ;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, RyzodegⓇ, NovoMix®, FiaspⓇ and
NovoRapidⓇ: 5 Comprises Novo NormⓇ and needles; 6 Obesity care comprises
SaxendaⓇ and Wegovy: 7 Comprises primarily Novo SevenⓇ, NovoEight®
NovoThirteenⓇ, Esperoct®, Refixia®, NorditropinⓇ, VagifemⓇ and ActivelleⓇView entire presentation